13 years of trabectedin, 5 years of Yondelis®: What have we learnt?

Expert Review of Anticancer Therapy

Volumn 13, Issue 6 SUPPL., 2013, Pages 11-19

  Le Cesne, Axel ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

doxorubicin; front line therapy; ifosfamide; safety; soft tissue sarcoma; targeted therapy; trabectedin; Yondelis

Indexed keywords

DOXORUBICIN; IFOSFAMIDE; TRABECTEDIN;

ADVANCED CANCER; ALVEOLAR SOFT PART SARCOMA; CANCER CLASSIFICATION; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLEAR CELL SARCOMA; CONFERENCE PAPER; CONTINUOUS INFUSION; DERMATOFIBROMA; DESMOPLASTIC SMALL ROUND CELL TUMOR; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM SARCOMA; EWING SARCOMA; FATIGUE; FEBRILE NEUTROPENIA; HISTOLOGY; HUMAN; MYXOSARCOMA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA CELL GRANULOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC AGENTS, ALKYLATING; CLINICAL TRIALS, PHASE II AS TOPIC; DIOXOLES; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; SARCOMA; TETRAHYDROISOQUINOLINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84877297872     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.13.49     Document Type: Conference Paper

References (35)

1. Demetri GD, Chawla SP, von Mehren M et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized Phase II study of two different schedules. J. Clin. Oncol. 27(25), 4188-4196 (2009).
2. Van Glabbeke M, Verweij J, Judson I, Nielsen OS; EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for Phase II trials in soft tissue sarcomas. Eur. J. Cancer 38(4), 543-549 (2002).
3. Le Cesne A, Domont J, Cioffi A et al. Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma. Drugs Today (Barc). 45(6), 403-421 (2009).
4. Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J. Clin. Oncol. 23(3), 576-584 (2005).
5. Yovine A, Riofrio M, Blay JY et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J. Clin. Oncol. 22(5), 890-899 (2004).
6. Garcia-Carbonero R, Supko JG, Manola J et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J. Clin. Oncol. 22(8), 1480-1490 (2004).
7. Jimeno J, Maki RG, Casali P et al. Therapeutic impact of ET-743 (Yondelis; trabectedin), a new marine-derived compound, in sarcoma. Curr. Opin. Orthop. 14(6), 419-428 (2003).
8. Verweij J, van Glabbeke M. Translating targets into treatment: changes in trial methodology and treatment approaches for soft tissue sarcomas. In: Classification and Treatment of Soft Tissue Sarcomas Educational Book. Perry MC (Ed.). American Society of Clinical Oncology, Alexandria, VA, USA, 522-530 (2003).
9. Ruiz-Soto R, Auger N, Tournay E. Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomas. Eur. J. Cancer 47(9), 1319-1327 (2011).
10. Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 8(7), 595-602 (2007).
11. Penel N, Demetri GD, Blay JY et al. Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. Ann. Oncol. 24(2), 537-42 (2012).
12. Cousin S, Blay JY, Bertucci F et al. Growth modulation index and RECIST-based STBSG-EORTC criteria for the assessment of drug activity in advanced soft tissue sarcoma (ASTS) patients (pts). J. Clin. Oncol. 30(Suppl.), Abstract 10014 (2012).
13. Le Cesne A, Yovine A, Blay JY et al. A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in Phase II clinical trials. Invest. New Drugs 30(3), 1193-1202 (2012).
14. Verweij J, Lee SM, Ruka W et al. Randomized Phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 18(10), 2081-2086 (2000).
15. Nielsen OS, Judson I, van Hoesel Q et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre Phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 36(1), 61-67 (2000).
16. Judson I, Radford JA, Harris M et al. Randomised Phase II trial of PEGylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 37(7), 870-877 (2001).
17. Le Cesne A, Antoine E, Spielmann M et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J. Clin. Oncol. 13(7), 1600-1608 (1995).
18. Sanfilippo R, Grosso F, Jones RL et al. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol. Oncol. 123(3), 553-556 (2011).
19. Blay JY. Trabectedin: an emerging therapeutic option in soft tissue sarcoma. Eur. J. Clin. Med. Oncol. 1(2) (2009).
20. López-González A, Cantos B, Tejerina E, Provencio M. Activity of trabectedin in desmoplastic small round cell tumor. Med. Oncol. 28(Suppl. 1), S644-S646 (2011).
21. Martinez-Trufero J, Alfaro J, Felipo F, Alvarez M, Madani J, Cebollero A. Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma. Anticancer Drugs 21(8), 795-798 (2010).
22. Chaigneau L, Kalbacher E, Thiery-Vuillemin A et al. Efficacy of trabectedin in metastatic solitary fibrous tumor. Rare Tumors 3(3), e29 (2011).
23. Le Cesne AL, Cresta S, Maki RG et al. A retrospective analysis of antitumour activity with trabectedin in translocationrelated sarcomas. Eur. J. Cancer 48(16), 3036-3044 (2012).
24. Gronchi A, Bui BN, Bonvalot S et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann. Oncol. 23(3), 771-776 (2012).
25. Sanfilippo R, Dileo P, Blay JY et al. Trabectedin (T) in advanced, pre-treated synovial sarcoma (SS): a retrospective analysis of 61 patients from four European institutions and from the Italian Rare Cancer Network. Presented at: 17th Annual Meeting of the Connective Tissue Oncology Society. Prague, Czech Republic, 14-17 November 2012.
26. Grosso F, Jones RL, Blay JY et al. Trabectedin in soft tissue sarcomas (STS) carrying a chromosomal translocation: an exploratory analysis. Presented at: 13th Annual Meeting of the Connective Tissue Oncology Society. Seattle, WA, USA, 1-3 November 2007 (Abstract 900).
27. Blay JY, Leahy MG, Bui BN et al. Randomized multicenter Phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy as first-line therapy in patients with translocation-related sarcoma (TRS). J. Clin. Oncol. 30(Suppl.), Abstract TPS10101 (2012).
28. Garcia-Carbonero R, Supko JG, Maki RG et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter Phase II and pharmacokinetic study. J. Clin. Oncol. 23(24), 5484-5492 (2005).
29. Blay JY, von Mehren M, Samuels BL et al. Phase I combination study of trabectedin and doxorubicin in patients with soft tissue sarcoma. Clin. Cancer Res. 14(20), 6656-6662 (2008).
30. Blay JY, Italiano A, Ray-Coquard I et al. Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. BMC Cancer 13, 64 (2013).
31. Saada E, Rahal C, Ray-Coquard I et al. Rechallenge with trabectedin in patients with locally advanced or metastatic soft tissue sarcoma following drug holiday: the experience of the French Sarcoma Group (FSG). J. Clin. Oncol. 30(Suppl.), Abstract 10062 (2012).
32. ClinicalTrials.gov. Doxorubicin hydrochloride or trabectedin in treating patients with previously untreated advanced or metastatic soft tissue sarcoma. http://clinicaltrials.gov/show/ NCT01189253
33. ClinicalTrials.gov. Clinical trial of doxorubicin versus trabectedin plus doxorubicin in the first line treatment of patients with advanced nonoperable and/or metastatic soft tissue sarcomas. http://clinicaltrials.gov/ct2/show/ NCT01104298
34. Institut de cancérologie Gustave Roussy willejuif. Les essais cliniques à l'IGR. www.igr.fr/index.php?p-m=igrinter&p- a=essai&p-sa=cancer-12
35. ClinicalTrials.gov. Continuing vs intermittent trabectedin-regimen in patients with advanced soft tissue sarcoma experiencing response or stable disease after the 6th cycle (T-DIS). http://clinicaltrials. gov/ct2/show/ NCT01303094